Clinical and transcriptional recovery profiles in pediatric and adult multiple sclerosis patients

Shay Menascu¹,²,a, Yulia Khavkin¹,a, Rina Zilkha-Falb¹, Mark Dolev¹, David Magalashvili¹, Anat Achiron¹,² & Michael Gurevich¹,²

¹Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, Israel
²Sackler School of Medicine, Tel-Aviv University, Tel Aviv, Israel

Correspondence
Michael Gurevich, Multiple Sclerosis Center, Sheba Medical Center, Ramat-Gan, 52621, Israel. Tel: +972 3 530 5785; Fax: +972 3 534 8186; E-mail: Michael.Gurevich@sheba.health.gov.il

Funding Information
No funding information is provided.

Accepted: 18 October 2020

Annals of Clinical and Translational Neurology 2021; 8(1): 81–94

doi: 10.1002/acn3.51244

Abstract

Objective: To determine whether pediatric-onset multiple sclerosis (POMS) and adults-onset multiple sclerosis (AOMS) patients are different in initial disease severity and recovery and to investigate the associations with peripheral blood mononuclear cells (PBMCs) transcriptional profiles. Methods: Clinical and radiological severity of first and second relapses and 6-month recovery were analyzed in 2153 multiple sclerosis (MS) patients and compared between POMS (onset at 8–18 years old) and AOMS (onset at 19–40 years old) patients. PBMCs transcriptomes of 15 POMS and 15 gender-matched AOMS patients were analyzed 6 months after the first relapse and compared to 55 age-matched healthy controls. Differentially Expressed Genes (DEGs) with a false discovery rate ≤ 10% were evaluated using the Partek software. Results: POMS had increased Expanded Disability Status Scale (EDSS) score at first and second relapses, higher brain gadolinium-enhancing T1-lesions volume at first relapse, and more complete recovery after both relapses compared to AOMS. POMS patients, who recovered completely from the first relapse, were characterized by 19 DEGs that were mainly related to suppression of antigen presentation. Six upstream regulators of these genes were differentially expressed between pediatric and adult healthy controls. POMS patients, who showed no recovery from the first relapse, were characterized by 28 DEGs that were mainly associated with B-cell activation. Five upstream regulators of these genes were differentially expressed between pediatric and adult healthy controls. Interpretation: POMS patients may have more severe first and second relapses than AOMS. However, most often, POMS have better recovery that may be attributed to PBMCs age-related transcriptional profiles associated with antigen presentation and B-cell activation.

Introduction

Age is a significant factor in multiple sclerosis (MS), affecting the disease’s phenotype and prognosis. Pediatric-onset MS (POMS), which occurs before 18 years of age, comprises 2-5% of all MS cases.¹,² POMS patients have more frequent polyfocal symptoms,³ higher relapse rate,⁴ higher rates of complete remission from initial relapse,⁵ and slower disease progression,²,⁶,⁷ in comparison to adult-onset MS (AOMS) patients. MS patients have a unique blood gene expression pattern related to activation of T-cell expansion, inflammatory cytokines and integrins, and suppression of anti-inflammatory cytokines and apoptosis.⁸-¹⁰ However, only a single study by Liguori et al. (2017)¹¹ addressed the underlying molecular mechanism of POMS, comparing microRNA and mRNA gene expression of 19 POMS patients with that of 20 controls. The study revealed 13 deregulated microRNAs that were associated with autophagy and ATPase activity.

In this study, we aimed to determine whether disease-modifying drugs (DMDs)-free POMS and AOMS patients are different in initial disease severity and recovery and to investigate the associations with peripheral blood mononuclear cells (PBMCs) transcriptional profiles.
Recovery from Multiple Sclerosis Attack

S. Menascu et al.

Patients and Methods

Study design

A retrospective cohort study of relapsing-remitting multiple sclerosis (RRMS) patients followed at Sheba Medical Center, Multiple Sclerosis Center (MSC) between 2003 and 2018. The study was approved by Sheba Medical Center Institutional Review Board. Informed consent was obtained from each subject or legal guardian.

Clinical and radiological severity of first and second MS relapses and 6-month recovery were analyzed and compared between POMS and AOMS patients. PBMCs transcriptomes in the subset of POMS and gender-matched AOMS patients were analyzed 6 months after the first relapse and compared to age-matched healthy controls.

Patients

MS patients were selected according to the following inclusion criteria:

a) POMS patients diagnosed according to the International Pediatric Multiple Sclerosis Study Group consensus definitions with disease onset at age ≤ 18 years;

b) AOMS patients with disease onset at age 19-40 years, diagnosed according to the 2010, 2013 2017 McDonald criteria;

c) A neurological examination within 2–21 days from initial clinical symptoms of either first or second relapse;

d) No DMDs treatment until 6 months after the second relapse;

e) For transcriptional analysis, PBMCs obtained 6 months after the first relapse from a subset of POMS and AOMS patients that were matched in gender and recovery state. PBMC obtained from gender- and age-matched healthy pediatric and adult subjects were used as healthy controls (HC), (Fig 1).

At first and second relapses, all patients were treated with high dose intravenous steroids. Patients that started DMDs treatment between the first and second relapses were excluded from the second relapse analysis.

Clinical analysis

Clinical data were retrieved from the computerized MSC’s database. The results of neurological examinations and Expanded Disability Status Scale (EDSS) scores performed at either first or second relapse as well as 6 months after each relapse, were obtained. The relapses were defined as the onset of new or worsening of existing neurological symptoms, persisting for at least 48 hours to 21 days, with objective findings in a clinical neurological examination. The first relapse was referred as disease onset, therefore the pre-relapse EDSS was defined as EDSS = 0. For the second relapse, pre-relapse EDSS was assessed within 3 months before the relapse. Patients that did not have a pre-second relapse EDSS score were not included in the study.

Brain magnetic resonance imaging (MRI) data were acquired using a 3.0-T MRI scanner (Signa; GE Healthcare, Chicago, IL, USA) with an axial T2-weighted sequence (slice thickness 3.0 mm, no gap, field of view 240 mm, matrix 256x256, repetition time 5,100, echo time 80). Lesions were identified by an experienced radiologist and the number and volume of the T2 and hypointensive T1 gadolinium-enchasing lesions were quantified using semiautomated segmentation analysis software (MSET-1.9, Matlab-12).

The following clinical parameters were used for comparing between POMS and AOMS patients: (a) EDSS at first relapse; (b) the number and volume of brain MRI T2 and hypointense T1 gadolinium-enchasing lesions; (c) the increase in EDSS at the first and second relapse calculated as the difference between peak EDSS during relapse and prerelapse EDSS; (d) the proportion of patients with EDDS increase ≥ 3.0 at the first and second relapse; (e) the number of impaired functional domains for both relapses; (f) residual disability 6 months after the first and second relapses, calculated as the difference between the 6-month post-relapse EDSS and the pre-relapse EDSS; and (g) clinical recovery, defined as a reduction of ≥ 1.0 EDSS points 6 months postrelapse as compared to the peak of EDSS during relapse. Complete recovery was defined as a residual disability of 0 EDSS points, and incomplete recovery as a residual disability ≥ 1.0 EDSS points.

Gene expression analysis

Transcriptional profiles of PBMCs obtained from POMS and AOMS patients at 6 months after the first relapse were analyzed using Affymetrix Inc. technology. This technology allows screening for a vast array of differentially expressed genes and is effective in discovering novel biological pathways. Briefly, PBMCs were separated on a ficollhypaque gradient. Total RNA was purified from PBMCs using TRIzol® (Invitrogen, Carlsbad, CA, USA) and Phase-Look-Gel columns (Eppendorf, Hamburg, Germany) including a DNase digestion step. RNA quality was assessed using Bio-Rad Experion Automated Electrophoresis Station (Hercules, CA, USA) and quantified by fiber optic spectrophotometry using the Nanodrop ND-1000. RNA yielding both an A260/A280 absorbance ratio greater than 2.0 and a 28s/18s rRNA ratio equal to or exceeding 1.8 was utilized. Double-stranded cDNA was
synthesized from 250 ng total RNA using the One-Cycle cDNA Synthesis Kit, and in vitro transcription was performed with the GeneChip IVT Labeling Kit (both Affymetrix Inc., Santa Clara, CA, USA). cDNA was labeled with streptavidin phycoerythrin, and biotin-labeled anti-streptavidin phycoerythrin antibodies. The biotin-labeled IVT-RNA was hybridized to HG-U133A-2 arrays (Affymetrix, Santa Clara, CA, USA) containing ~22,000 gene transcripts corresponding to 14,500 well-annotated human genes. The microarrays were then washed in a Gene-Chip Fluidics Station 450 and scanned on a GeneArray-TM scanner (G2500A; Hewlett Packard Palo Alto, California, USA) according to the standard Affymetrix Inc. protocol.

**Statistical analysis**

**Clinical analysis**

Clinical and demographical data were presented as mean (95% confidence interval [CI]). Continuous variables were analyzed using two samples t-test. The proportion of patients with first- and second relapse EDSS score ≥ 3.0 and the proportion of patients with incomplete recovery 6 months after relapses were examined by logistic regression. The odds ratio (OR) and 95% CI were calculated using a multivariate model. A p-value of ≤ 0.05 was deemed statistically significant. Gender-specific effects were also analyzed.

**Gene expression analysis**

Gene expression data were normalized using R, an open-source software environment for statistical computing. Two methods of normalization were applied:

a. Single Channel Array Normalization – a serial normalization method that increases signal-to-noise ratio within individual samples and decreases variation across samples.

b. Combining Batch Normalization – a method for solving batch effects on data that allows combining results from different batches.

The Partek Genomics Software was used to evaluate Differentially Expressed Genes (DEGs) with False Discovery Rate (FDR) ≤ 10% after correction for multiple comparisons. DEGs between POMS and AOMS patients, for both, post-relapse clinically recovered and non-recovered patients were evaluated. Using the Ingenuity Pathway Analysis (IPA) software, potential upstream regulating genes for these DEGs were identified. These upstream regulators with their downstream target DEGs were tested for their contribution to the PBMCs transcriptional differences between healthy pediatric and adult controls.

The transcriptional data were deposited in NCBI’s Gene Expression Omnibus (GEO), GEO Series accession number GSE146383 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE146383).
Six months after the first relapse, the mean EDSS score was 1.3 (95% CI: 1.2–1.4) and 79.2% of patients had residual disability ≥1.0 EDSS point. POMS patients were associated with a lower proportion of patients with residual disability ≥1.0 points compared to AOMS (OR = 3.20, 95% CI: 1.31–7.79), P = 0.01, Figure 2B.

The analysis of the effect of first-relapse EDSS severity on recovery 6 months later showed that, as expected, EDSS ≥3.0 at relapse was strongly associated with a higher proportion of patients with incomplete recovery 6 months later (OR = 12.8, 95% CI: 8.5–19.4), P < 0.001. Interestingly, when the same analysis was performed separately on POMS and AOMS patients, higher EDSS at relapse was associated with poor recovery only AOMS patients (OR = 4.7, 95% CI: 3.2–6.8, P < 0.001), whereas in POMS patients good recovery was observed independently from EDSS at relapse (OR = 1.1, 95% CI: 0.7–2.9, P = 0.16).

The Difference between POMS and AOMS patients in second relapse severity and recovery

On average, the second relapse occurred significantly earlier in POMS patients compared to AOMS patients: 0.9 years (95% CI: 0.8–1.1 years) vs. 3.5 years (95% CI: 3.2–3.8 years) after first relapse, respectively, P = 0.01. Mean EDSS before the second relapse was similar in both populations: 1.4 (95% CI: 1.3–1.5) for POMS and 1.3 (95% CI: 1.3–1.5) for AOMS patients. Although the mean EDSS-increase at second relapse was greater in POMS compared to AOMS patients: 1.5 (95% CI: 1.2–1.8) vs. 1.2 (95% CI: 1.2–1.6), P = 0.05, the proportion of patients with EDSS increase ≥3.0 was similar in both groups (45% and 41%, respectively, P = 0.5). The polysymptomatic functional system presentation was 46% in the POMS patients and 49% in the AOMS populations with a mean of 1.7 (95% CI: 1.5–1.9) impaired functional domains in both groups.

AOMS was also associated with a higher proportion of incomplete recoveries after the second relapse (OR = 1.4, 95% CI: 1.04–1.9), P = 0.02. This effect was significant only in males but not in females (OR = 1.9, 95% CI 1.1–3.2, P = 0.01 and OR = 1.2, 95% CI 0.8–1.7, p = 0.3, respectively). The proportion of AOMS patients with incomplete recovery demonstrated a tendency for an association with EDSS increase at second relapse (OR = 0.67, 95% CI 0.44–1.03, P = 0.06).

In order to test the hypothesis that clinical presentation of second relapse is more affected by age at second relapse than by age of onset, second relapse severity and recovery were compared between MS patients with pediatric age (<18 years old) and adult age (19–40 years old) at time of...
Figure 2. Severity and recovery of first MS relapse in POMS and AOMS patients. (A) The proportion of MS patients with EDSS scores ≥ 3.0 at first MS relapse by age at first relapse. Pediatric MS onset is associated with a higher proportion of patients with more severe disability ($P < 0.001$). (B) The proportion of MS patients with residual disability (EDSS ≥ 1.0) 6 months after the first MS relapse by age at onset. Pediatric MS onset is associated with lower residual disability ($P = 0.01$).
second relapse. The results demonstrated that the proportion of patients with an EDSS increase ≥ 3.0 at second relapse and the proportion of patients with incomplete recovery were not significantly different between pediatric and adult MS patients (OR = 0.74, 95% CI: 0.50–1.11, P = 0.2 and OR = 1.30, 95% CI: 0.72–2.34, P = 0.3, respectively). Next, we excluded 109 POMS patients who had a second relapse at age >18 years, and AOMS with a second relapse at age > 40 years, leaving 1046 patients whose age status did not change during the follow-up period. In this subanalysis, in the POMS patients, the proportion of patients with EDSS ≥ 3.0 at second relapse was higher (OR = 0.26, 95% CI: 0.17–0.40, P < 0.01) and the proportion of patients with incomplete recovery was lower (OR = 1.77, 95% CI 0.98–3.2, P = 0.05). These results suggest that second relapse severity and recovery are more associated with the age of MS onset.

In addition, by applying ANOVA model to compare second relapse severity between POMS patients who remained pediatric at second relapse, POMS who had second relapse at adult age, and AOMS, we have confirmed that EDSS at second relapse more significantly associated with age at onset (P = 0.02) than with age of second relapse (P = 0.2).

**Effect of gender on first- and second relapse severity and recovery**

No association was noted between gender and severity of first and second relapse (OR = 1.04, 95% CI: 0.85-1.27, P = 0.7, OR = 1.0, 95% CI: 0.79–1.33, P = 0.8, respectively). Gender was also not associated with the proportion of patients showing incomplete recovery 6 months after the first two relapses (OR = 0.98, 95% CI: 0.74–1.3, P = 0.9 and OR = 0.85, 95% CI: 0.58–1.25, P = 0.4, respectively).

**Age-related PBMCs transcriptional profiles associated with recovery from first MS relapse**

Fifteen POMS patients, mean age 15.5 years (95% CI: 14.8–16.2 years), F/M ratio 1.1:1, mean EDSS at first relapse 3.1 (95% CI: 2.6–3.5), and 15 AOMS patients, mean age 31.9 years (95% CI: 28.9–34.8 years), F/M ratio 1.1:1, mean EDSS at first relapse 2.6 (95% CI: 2.1-3.1), donated blood samples for gene expression analysis. An age- and gender-matched healthy cohort (n = 55) consisting of 46 adults, mean age 34.4 years (95% CI: 32.6–36.3 years), F/M ratio 1.1:1 and nine pediatric subjects, mean age 13.9 years (95% CI: 11.6–16.3), F/M ratio 1.2:1 were enrolled.

PBMCs transcriptional profiles were compared between POMS (n = 8) and AOMS (n = 6) patients who showed a clinical recovery ≥ 1.0 EDSS with mean residual disability of 1.0 (95% CI: 0.6–1.6) and 1.5 (95% CI: 0.8–2.3), respectively, 6 months after relapse. POMS (n = 7) and AOMS (n = 9) patients whose EDSS did not change 6 months after relapse and did not show clinical recovery were also compared.

| DEGs Name | DEGs Title | Fold/Change Direction |
|-----------|------------|-----------------------|
| HLA-DQ61  | major histocompatibility complex, class II, DQ beta 1 | Down |
| HLA-DQA1  | major histocompatibility complex, class II, DQ alpha 1 | Down |
| MID2      | midline 2  | Down |
| NAP1L3    | nucleosome assembly protein 1-like 3 | Down |
| EDN1      | endothelin 1 | Down |
| OGG1      | 8-oxoguanine DNA glycosylase | Down |
| CACNA1l   | calcium channel, voltage-dependent, T type, alpha 11 subunit | Down |
| HSPA4L    | heat shock 70kDa protein 4-like | Up |
| WSB2      | WD repeat and SOCS box containing 2 | Up |
| BYS1      | bystin-like | Up |
| RAB27A    | RAB27A, member RAS oncogene family | Up |
| GPC4      | glypican 4 | Up |
| ARHGEF12  | Rho guanine nucleotide exchange factor (GEF) 12 | Up |
| KCTD14    | potassium channel tetramerization domain containing 14 | Up |
| MSL1      | musashi RNA-binding protein 1 | Up |
| ENPP-4    | ectonucleotide pyrophosphatase/phosphodiesterase 4 | Up |
| CEP1      | carboxyl ester lipase pseudogene | Up |
| DBI       | diazepam-binding inhibitor | Up |
| MCF2L2    | MCF-2-cell line-derived transforming sequence-like 2 | Up |

Table 1. DEGs between post-relapse recovered POMS and AOMS patients.

DEGs, Differentially Expressed Genes.
Comparison between PBMCs gene expression profiles of POMS and AOMS patients that showed clinical recovery after their first relapse revealed 19 DEGs, that were mainly associated with underexpression of antigen-presenting mechanisms ($P = 1.36E-3$). These DEGs included genes like HLA-DQA1, HLA-DQB1, END1, and RAB27A, as well as more highly expressed apoptosis-related genes such as ARHGEF12 (Table 1).

The analysis of upstream regulators of these 19 DEGs revealed 109 potential regulators (Table S1). To test the hypothesis that these regulators and their 19 downstream DEGs could be part of the transcriptional difference between healthy pediatric and adult subjects, PBMC expression profiles of these two healthy groups were compared, revealing 257 DEGs (Table S2). Of the 109 potential upstream regulators mentioned above, six were differentially expressed ($P < 0.004$) between healthy pediatric and adult controls: COL1A1, MEF2A, VEZF1, HLAB, KBM3A, PLK2 (Fig. 3). All six upstream regulators could affect the one downstream END1 gene (Fig. 4A).

Comparison between PBMC expression profiles of POMS and AOMS patients that showed no recovery after their first relapse revealed 28 DEGs. These DEGs are mainly associated with activation of B-cell development.
(P = 3.39E-7), B-cell proliferation (P = 1.70E-12), and B-cell receptor signaling (P = 7.0E-08) and included genes such as CD19, CD22, MS4A1, BCL7A, IGHM, IGHD, CD79A, BLNK, FCER2, CR2, PAX5, IL4R, and STAP1 (Table 2). In addition, 152 potential upstream regulators were identified for these 28 DEGs (Table S3) of which five (CD47, REL, HNRNPD, FOXO1, and IL7R) were differentially expressed (P < 0.001) between healthy pediatric and adult controls (Fig. 5). These upstream regulators could affect CD19, CD79, IGHM, PAX5, FCER2, and CR2 DEGs which were differentially expressed between POMS and AOMS patients that showed no recovery after first relapse (Fig. 4B).

**Discussion**

We evaluated the role of pediatric and adult ages of MS onset in the heterogeneity of the first and second MS relapse severity and recovery in a large cohort of DMDs-free RRMS patients with disease onset of 8–40 years. Our findings show, that although POMS patients may have more severe first and second relapse than AOMS, their recovery from relapse is often better and independent of relapse severity, as demonstrated by lower residual disability six months later. An association between relapse severity and less efficient recovery was only observed in the AOMS patients. Age-related underexpression of PBMCs genes involved in antigen-presenting functions or to overexpression of B-cell associated genes is attributed to the difference noted between POMS and AOMS with regard to the recovery from acute MS relapse.

The difference between POMS and AOMS features has been reported in previous publications. Our clinical observation is in complete agreement with several retrospective American and European reports that concluded that POMS patients have more severe onset but better recovery and slower disability accumulation as compared with AOMS patients.

Previous studies have analyzed relapse recovery in patient cohorts with variable treatments and clinical presentations. Moreover, the intervals between relapse and postrelapse EDSS assessment ranged from a single month
to year, leading to inconsistent results in relation to the duration of postrelapse recovery and the level of postrelapse residual disability. Studies with relatively short intervals between relapse and postrelapse EDSS analysis may overestimate the residual disability level, thus the patient not have reached the end of their recovery. In contrast, studies with relatively large intervals for post-relapse EDSS assessments may have had an EDSS bias associated with disease progression. We chose to measure recovery 6 months after relapse following studies by Hirst et al. (2008), Koch-Henriksen et al. (2019), and Novotna et al. (2015), that have suggested that most patients recover 3–6 months after the relapse. For example, Hirst et al. (2008) measured post-relapse EDSS for 36–496 days, and reported that recovery changes took place until 180 days post-relapse.

In order to clarify whether the age of onset or age at second relapse have a more robust effect on second relapse outcome, we compared the second relapse clinical parameters only in POMS patients that were younger than 18 years during follow-up, to those of AOMS patients who were younger than 40 years during follow-up. The obtained results support the hypothesis that second relapse severity and recovery depend mostly on the age of MS onset.

According to our results, 79.2% of patients had an incomplete recovery after the first relapse. This percentage is greater than the previously reported range of 34% by Leone et al. (2008), 24% by Lublin et al. (2003), 49.9% by Hirst et al. (2008), 53.3% by Kantarci et al. (2020), 54.5% by Vercellino et al. (2009), and 56.9% by West et al. (2006). Directly comparable studies are limited. West et al. (2006) analyzed the recovery of 186 MS patients following their first demyelinating event. These patients had various EDSS levels: 41.9% had mild (EDSS 0–1.5), 44.1% had moderate (EDSS 2.0–2.5), and 14% had severe (EDSS> 2.5). Incomplete recovery was reported for 59.6% of patients that is somewhat lower than our observation of 79.2%. Our finding may be explained by the fact that we included patients with more severe disease onset (EDSS 2.0–3.0), whereas in West et al. study (2006) more than 40% of patients had onset EDSS between 0 and 1.5. This may have led to an underestimation of the first relapse residual disability in West

### Table 2. DEGs between post-relapse non-recovered POMS and AOMS patients.

| DEGs Name | DEGs Title                                      | Fold/Change Direction |
|----------|------------------------------------------------|-----------------------|
| C16orf3  | chromosome 16 open reading frame 3             | Down                  |
| APH1B    | anterior pharynx defective 1 homolog B (C. elegans) | Down                  |
| SQRDL    | sulfide quinone reductase-like (yeast)         | Down                  |
| SAMSN1   | SAM domain, SH3 domain, and nuclear localization signals 1 | Down                  |
| HTATIP2  | HIV-1 Tat interactive protein 2, 30kDa        | Down                  |
| ENY2     | enhancer of yellow 2 homolog (Drosophila)     | Down                  |
| ACSS1    | acyl-CoA synthetase long-chain family member 1 | Down                  |
| COX7B    | cytochrome c oxidase subunit VIIb              | Down                  |
| FPR2     | formyl peptide receptor 2                      | Down                  |
| CD19     | CD19 molecule                                  | Up                    |
| BCL7A    | B-cell CLL/lymphoma 7A                         | Up                    |
| IGHM     | immunoglobulin heavy constant mu               | Up                    |
| CD22     | CD22 molecule                                  | Up                    |
| IGHD     | immunoglobulin heavy constant delta            | Up                    |
| M54A1    | membrane-spanning 4-domains, subfamily A, member 1 | Up                    |
| PAFR     | PRKC, apoptosis, WT1, regulator                | Up                    |
| ABCB4    | ATP-binding cassette, subfamily B (MDR/TAP), member 4 | Up                    |
| FADS3    | fatty acid desaturase 3                        | Up                    |
| PCDH9    | protocadherin 9                                | Up                    |
| CD79A    | CD79a molecule, immunoglobulin-associated alpha | Up                    |
| MARCH3   | membrane-associated ring finger (C3HC4) 3       | Up                    |
| TCF4     | transcription factor 4                         | Up                    |
| BLNK     | B-cell linker                                  | Up                    |
| IL4R     | interleukin 4 receptor                         | Up                    |
| FCER2    | Fc fragment of IgE, low affinity II, receptor for (CD23) | Up                    |
| CR2      | complement component (3d/Epstein Barr virus) receptor 2 | Up                    |
| TCL1A    | T-cell leukemia/lymphoma 1A                    | Up                    |
| STAP1    | signal transducing adaptor family member 1     | Up                    |

DEGs, Differentially Expressed Genes.
et al. study. Notably, the authors reported that among those with severe onset, only 23.1% had complete recovery, meaning that 76.9% of patients had different levels of residual disability which is in complete agreement with our findings. A similar trend was reported by Lublin et al. (2003) whereby 37.5% of included patients had no worsening of EDSS score during relapse and when residual disability was calculated in subgroups that experienced EDSS worsening during relapse, the rate of post-relapse residual disability increased from 42% to 57%. Therefore, even if relapse severity is based on different definitions, our study and others show that higher severity of the initial relapse is associated with higher post-relapse residual disability. In addition, as only DMDs-free patients were included in our study, this could contribute to the relatively higher incomplete relapse recovery.

The involvement of antigen presentation, in recovery mechanism is not surprising, since these processes are known to play a role in MS disease course and in MS susceptibility presented by polymorphism of HLA-DQB1, IL4R, and HSP97 genes. A review by Anagnostouli et al. (2018) concluded that while HLA-DRB1*1501 is clearly a risk factor for both POMS and

Figure 5. Venn diagram of numeric gene expression results of post-relapse non-recovered MS patients. A total 28 DEGs (green circle) differentiated between post-relapse non-recovered POMS and AOMS patients. These DEGs are regulated by 152 upstream regulators (blue crescent). 257 DEGs differentiate between healthy pediatric and adult subjects (red circle). Of these, five were included in the 152 upstream regulating genes and involved in regulating six of 28 DEGs that differentiated between post-relapse non-recovered POMS and AOMS patients.
AOMS patients, the results regarding the association between HLA-DRB1 variability and age of MS onset are conflicting: some studies describe HLA-DRB1*1501 as being associated with an earlier onset age, whereas others claim that there is no correlation between HLA-DRB1*1501 and age. Of note, the HLA-DRB1*1501 allele, which is known to increase the risk for developing MS, is associated with a high expression level of HLA-DQB1. It is therefore possible that the underexpression of this gene in POMS patients compared to AOMS could be also a result of a lower prevalence of this allele in this subgroup.

In order to distinguish the role of pediatric-onset and adult-onset age in the MS post-relapse recovery process, we performed an Ingenuity® Knowledge Base Upstream Regulator analysis. We identified upstream regulators of DEGs that differentiate between post-relapse recovered and non-recovered POMS and AOMS patients. Some of these upstream regulators were also differentially expressed between healthy adult and pediatric controls. These findings suggest that age could contribute to the difference in recovery potential between POMS and AOMS patients.

Interestingly, all upstream regulators of DEGs between post-relapse recovered POMS and AOMS affect END1 gene expression, which was found to be underexpressed. END1 has proinflammatory function through activation of NF-κB and expression of cytokines such as TNF-α, IL-1, and IL-6. Specifically, it plays a role in antigen presentation: dendritic cells, the major antigen-presenting cells of the adaptive immune system, express END1. END1 is also overexpressed in other autoimmune diseases such as vasculitis.

The age-related upstream regulators of DEGs between post-relapse non-recovered POMS and AOMS patients affect genes that are associated with B-cell activation (CD19, CD79A, IGHM, and PAX5). Correlation of incomplete recovery with age-dependent B-cell gene expression is one of the interesting observations of our study. In MS B cells are employed as precursors of antibody-secreting cells, driving inflammation through the production of cytokines and chemokines or as antigen-presenting cells by expressing MHC class II molecules, upregulating costimulatory molecules, and presenting their cognate antigen for activation of antigen-specific T cell. Despite the known efficacy of B-cell depleting therapies, data on differences in B-cell-associated autoimmune mechanisms in pediatric and adults MS onset patients are limited. One study reported that circulating anti-myelin oligodendrocyte glycoprotein (anti-MOG) antibodies was strongly correlated with the age of MS onset. These antibodies, which can fix the complement and bind to Fc causing damage to oligodendrocytes were present in 38.7% of pediatric patients whose MS disease onset occurred at under 10 years of age, in 14.7% of patients whose disease onset occurred at 10–18 years of age, and only in 4% of AOMS patients. One can speculate that overexpression of B-cell-related genes, as we have observed in a subset of post-relapse non-recovered POMS patients, could be associated with such anti-MOG reactivity.

Better recovery, regardless of relapse severity, in POMS patients in contrast to the correlation between recovery and relapse severity in AOMS patients could be attributed to neuroplasticity, or to the ability of the central nervous system to recover from damage through the structural and functional changes, including myelin formation, which is most remarkable in children but continues up to the age of 18 years. The significant effect of age on recovery has been well studied in animal models, and seems to be related to deterioration of signaling of oligodendrocyte precursors (OPC) with aging. It was demonstrated that aged OPC have a diminished ability to differentiate due to age-related DNA damage and mitochondrial dysfunction and indirectly affected by the reduced ability of aged supporting cells (macrophages, microglia, and astrocytes) to produce proremyelination factors and remove myelin debris.

Some limitations must be considered in our study. First, our analyses were confined to the natural history of the first and second MS relapses in DMDs-free MS patients; therefore, our findings cannot be applied to subsequent or DMDs-treated relapses. Second, during relapses, all patients were treated with high-dose intravenous steroids for five subsequent days. The possibility that steroids treatment interferes with natural recovery mechanisms should be considered. Third, we used EDSS as a measure of MS relapse severity and recovery. Some argue that the lower values of the EDSS measure impairments based on the neurological examination, whereas the higher values of the EDSS focus on walking ability. Therefore, changes between steps on the scale are unequal and some functions such as cognition, energy level, pain or spasticity are not assessed, so that clinical outcome assessed by EDSS may have a lower limit of responsiveness. Lastly, although the clinical differences between POMS and AOMS patients were demonstrated in a large cohort of RRMS patients, only a relatively small number of patients donated blood for gene expression analysis. Nevertheless, the extensive analysis of clinical and transcriptional changes in all eligible patients enabled us to reveal the differences between POMS and AOMS patients in relapse-related clinical outcomes and to suggest underlying biological mechanisms that could explain the clinical observations.
In conclusion, POMS patients may suffer from more severe neurological disability at first and second relapses; they more often show better recovery and lower residual disability. Short-term clinical outcomes of MS may be modulated by age-related differences in PBMCs transcriptional profiles. Improved recovery among POMS patients may be associated with the underexpression of antigen-presenting mechanism, whereas the lack of recovery may be associated with overexpression of B-cell-related genes.

Conflict of Interest

There are no financial disclosures relevant to the manuscript (no other study funding) and no conflicts of interest.

Funding Information

No funding information is provided.

References

1. Chitnis T, Glanz B, Jaffin S, Healy B. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Mult Scler 2009;15:627–631.
2. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007;356:2603–2613.
3. Alroughani R, Boyko A. Pediatric multiple sclerosis: a review. BMC Neurol. 2018;18:27.
4. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis. Arch Neurol 2009;66:54–59.
5. McKay KA, Hillert J, Manouchehrinia A. Long-term disability progression of pediatric-onset multiple sclerosis. Neurology 2019;92(24):e2764–e2773.
6. Harding KE, Liang K, Cossburn MD, et al. Long-term outcome of paediatric-onset multiple sclerosis: a population-based study. J Neurol Neurosurg Psychiatry 2013;84:141–147.
7. Benson LA, Healy BC, Gorman MP, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord 2014;3:186–193.
8. Achiron A, Gurevich M, Friedman N, et al. Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol 2004;55:410–417.
9. Achiron A, Feldman A, Mandel M, Gurevich M. Impaired expression of peripheral blood apoptotic-related gene transcripts in acute multiple sclerosis relapse. Ann N Y Acad Sci 2007;1107:155–167.
10. Tajouri L, Fernandez F, Griffiths LR. Gene expression studies in multiple sclerosis. Curr Genomics 2007;8:181–189.
11. Liguori M, Nuzziello N, Licciulli F, et al. Combined microRNAs and mRNAs expression analysis in Pediatric Multiple Sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. Hum Mol Genet 2017.
12. Krupp LB, Tardieu M, Amato MP, et al. International Pediatric Multiple Sclerosis Study Group criteria for pediatric multiple sclerosis and immune-mediated central nervous system demyelinating disorders: revisions to the 2007 definitions. Mult Scler 2013;19:1261–1267.
13. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69:292–302.
14. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–173.
15. Langille MM, Islam T, Burnett M, Ameczua L. Clinical characteristics of pediatric-onset and adult-onset multiple sclerosis in hispanic Americans. J Child Neurol 2016;31:1068–1073.
16. Huppke B, Ellenberger D, Rosewich H, et al. Clinical presentation of pediatric multiple sclerosis before puberty. Eur J Neurol 2014;21:441–446.
17. Waldman A, Ness J, Pohl D, et al. Pediatric multiple sclerosis: Clinical features and outcome. Neurology 2016;87(Suppl 2):S74–81.
18. Fay AJ, Mowry EM, Strober J, Wauhant E. Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler 2012;18:1008–1012.
19. Musella A, Gentile A, Rizzo FR, et al. Interplay between age and neuroinflammation in multiple sclerosis: effects on motor and cognitive functions. Front Aging Neurosci 2018;10:238.
20. Hirst C, Ingram G, Pearson O, et al. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008;255:280–287.
21. Koch-Henriksen N, Thygesen LC, Sorensen PS, Magvary M. Worsening of disability caused by relapses in multiple sclerosis: a different approach. Mult Scler Relat Disord 2019;32:1–8.
22. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003;61:1528–1532.
23. Novotna M, Paz Soldán MM, Abou Zeid N, et al. Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology 2015;85:722–729.
24. Leone MA, Bonissoni S, Collimedaglia L, et al. Factors predicting incomplete recovery from relapses in multiple sclerosis: a prospective study. Mult Scler 2008;14:485–493.
25. Kantarci OH, Zeydan B, Atkinson EJ, et al. Relapse recovery: The forgotten variable in multiple sclerosis clinical trials. Neurou Neuroimmunol Neuroinflamm. 2020;7.
26. Vercellino M, Romagnolo A, Mattioda A, et al. Multiple sclerosis relapses: a multivariable analysis of residual disability determinants. Acta Neurol Scand 2009;119:126–130.

27. West T, Wyatt M, High A, et al. Are initial demyelinating event recovery and time to second event under differential control? Neurology 2006;67:809–813.

28. Achiron A, Saroiva-Pinhas I, Magalashvili D, et al. Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy. Mult Scler 2018;1352485188093.

29. Kollaee A, Ghaffarpor M, Ghlichnia HA, et al. The influence of the HLA-DRB1 and HLA-DQB1 allele heterogeneity on disease risk and severity in Iranian patients with multiple sclerosis. Int J Immunogenet 2012;39:414–422.

30. Cierny D, Lehotsky J, Kantorová E, et al. The HLA-DRB1 and HLA-DQVB1 alleles are associated with multiple sclerosis disability progression in Slovak population. Neurol Res 2018;40:607–614.

31. Stamateles P. HLA-Genotype in Multiple Sclerosis: The Role in Disease onset, Clinical Course, Cognitive Status and Response to Treatment: A Clear Step Towards Personalized Therapeutics. In: Anagnostoulli M, editor. Immunogenetics: Open access 2017.

32. Mirel DB, Barcellos LF, Wang J, et al. Analysis of IL4R haplotypes in predisposition to multiple sclerosis. Genes Immun 2004;5:138–141.

33. Mansilla MJ, Comabella M, Rio J, et al. Up-regulation of inducible heat shock protein 70-hom gene polymorphism and protein expression in multiple sclerosis patients. Autoimmunity 2014;47(2):127–.

34. Boiocchi C, Monti MC, Osera C, et al. Heat shock protein 70-hom gene polymorphism and protein expression in multiple sclerosis. J Neuroimmunol 2016;09:189–193.

35. Anagnostoulli M, Gontika M. HLA Allele Frequencies in Pediatric and Adolescent Multiple Sclerosis Patients. 2018.

36. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol 2007;165:1097–1109.

37. Dyment DA, Sadovnick AD, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Hum Mol Genet 1997;6:1693–1698.

38. Alcina A, McM A-G, Fedetz M, et al. Multiple sclerosis risk variant HLA-DRB1*1501 associates with high expression of DRB1 gene in different human populations. PLoS One 2012;7(1):e29819.

39. Kowalczyk A, Kleniewska P, Kolodziejczyk M, et al. The role of endothelin-1 and endothelin receptor antagonists in inflammatory response and sepsis. Arch Immunol Ther Exp (Warsz) 2015;63:41–52.

40. Guruli G, Pfug BR, Pecher S, et al. Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops. Blood 2004;104:2107–2115.

41. Kobayashi S, Ito A, Okuzaki D, et al. Expression profiling of PBMC-based diagnostic gene markers isolated from vasculitis patients. DNA Res 2008;15:253–265.

42. Pröbstel AK, Sanderson NS, Derfluss T. B Cells and Autoantibodies in Multiple Sclerosis. Int J Mol Sci 2015;16:16576–16592.

43. Molnarfi N, Schulze-Topphoff U, Weber MS, et al. MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. J Exp Med. 2013;210:2921–2937.

44. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009;183:4067–4076.

45. Tomassini V, Matthews PM, Thompson AJ, et al. Neuroplasticity and functional recovery in multiple sclerosis. Nat Rev Neurol. 2012;8:635–646.

46. Koll B, Gibb R. Brain plasticity and behaviour in the developing brain. J Can Acad Child Adolesc Psychiatry 2011;20:265–276.

47. Ksiazek-Winiarek DJ, Szpakowski P, Glabinski A. Neural Plasticity in Multiple Sclerosis: The Functional and Molecular Background. Neural Plast 2015;2015:307175.

48. Wright J, Zhang G, Yu TS, Kernie SG. Age-related changes in the oligodendrocyte progenitor pool influence brain remodeling after injury. Dev Neurosci 2010;32:499–509.

49. Spitzer SO, Sitnikov S, Kamen Y, et al. Oligodendrocyte progenitor cells become regionally diverse and heterogeneous with age. Neuron 2019;101:459-71.e5.

50. van Wijngaarden P, Franklin RJ. Ageing stem and progenitor cells: implications for rejuvenation of the central nervous system. Development 2013;140:2562–2575.

51. Meyer-Moock S, Feng YS, Maeurer M, et al. Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis. BMC Neurol. 2014;14:58.

52. Demir S. Multiple sclerosis functional composite. Noro Psikiyatr Ars 2018;55(Suppl 1):S66–S68.

Supporting Information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Upstream regulators of 19 recovery associated DEGs. Upstream regulators analysis revealed 109 potential regulators for 19 DEGs between POMS and AOMS patients that showed clinical recovery after their first relapse. DEGs – Differentially Expressed Genes, POMS – Pediatric Onset Multiple Sclerosis, AOMS – Adult Onset Multiple Sclerosis.
Table S2. DEGs between pediatric and adult healthy controls. 257 DEGs between healthy pediatric (age ≤ 18 years old) and adults (age 19–40 years old) controls. DEGs – Differentially Expressed Genes

Table S3. Upstream regulators of 28 DEGs associated with no recovery. Upstream regulators analysis revealed 152 potential regulators for 28 DEGs between POMS and AOMS patients that showed no clinical recovery after their first relapse. DEGs – Differentially Expressed Genes, POMS – Pediatric Onset Multiple Sclerosis, AOMS – Adult Onset Multiple Sclerosis